Document:

Ex-10.4 Form of Option Agreement

 

Exhibit 10.4

BIOHEART, INC.

NON-QUALIFIED STOCK OPTION AGREEMENT

FOR

Agreement

     1. Grant of Option. BIOHEART, INC. (the “Company”) hereby grants, as of                 , (the “Date
of Grant”),                  (the “Optionee”) an option (the “Option”) to purchase up to                  shares of the Company’s
Common Stock, $.001 par value (the “Stock”), at an exercise price per share equal to $3.50 (the
“Exercise Price”). The Option shall be subject to the terms and conditions set forth herein. The
Option was issued pursuant to the Company’s 1999 Directors and Consultants Stock Option Plan (the
“Plan”), which is incorporated herein for all purposes. The Option is a nonqualified stock option,
and not an incentive stock option within the meaning of Section 422 of the Internal Revenue Code of
1986, as amended (the “Code”). The Optionee hereby acknowledges receipt of a copy of the Plan and
agrees to be bound by all of the terms and conditions hereof and thereof.

     2. Definitions. Unless otherwise provided herein, terms used herein that are defined
in the Plan and not defined herein shall have the meanings attributed thereto in the Plan.

     3. Exercise Schedule. Except as otherwise provided in Section 6 or 12 of this
Agreement, or in the Plan, the Option is exercisable in installments as provided below, which shall
be cumulative. To the extent that the Option has become exercisable with respect to a percentage of
Shares as provided below, the Option may thereafter be exercised by the Optionee, in whole or in
part, at any time or from time to time prior to the expiration of the Option as provided herein.
The following table indicates each date (the “Vesting Date”) upon which the Optionee shall be
entitled to exercise the Option with respect to the percentage of Shares granted as indicated
beside the date, provided that the Optionee has continuously provided services to the Company or a
Subsidiary through and on the applicable Vesting Date:

	 	 	 
	Percentage of Shares	 	Vesting Date
	 
	 	 
	33 1/3%

	 	first anniversary of Date of Grant
	33 1/3%

	 	second anniversary of Date of Grant
	33 1/3%

	 	third anniversary of Date of Grant

     Except as otherwise specifically provided herein, there shall be no proportionate or partial
vesting in the periods prior to each Vesting Date, and all vesting shall occur only on the
appropriate Vesting Date. Upon an Optionee’s termination of service with the Company and its
Subsidiaries, any unvested portion of the Option shall terminate and be null and void.

     4. Method of Exercise. This Option shall be exercisable in whole or in part in
accordance with the exercise schedule set forth in Section 3 hereof by written notice which shall
state the election to exercise the Option, the number of Shares in respect of which the Option is

 

 

being exercised, and such other representations and agreements as to the holder’s investment intent
with respect to such Shares as may be required by the Company pursuant to the provisions of the
Plan. Such written notice shall be signed by the Optionee and shall be delivered in person or by
certified mail to the Chief Financial Officer of the Company. The written notice shall be
accompanied by payment of the Exercise Price. This Option shall be deemed to be exercised after
(a) receipt by the Company of such written notice accompanied by the Exercise Price, and (b)
arrangements that are satisfactory to the Board or the Committee in its sole discretion have been
made for Optionee’s payment to the Company of the amount that is necessary to be withheld in
accordance with applicable Federal or state withholding requirements. No Shares will be issued
pursuant to the Option unless and until such issuance and such exercise shall comply with all
relevant provisions of applicable law, including the requirements of any stock exchange upon which
the Stock then may be traded.

     5. Method of Payment. Payment of the exercise price shall be by any of the
following, or a combination thereof, at the election of the Optionee: (a) cash; (b) check; (c)
with Shares that have been held by the Optionee for at least 6 months (or such other Shares as the
Company determines will not cause the Company to recognize for financial accounting purposes a
charge for compensation expense); or (d) such other consideration or in such other manner as may be
determined by the Board or the Committee in its absolute discretion.

     6. Termination of Option.

     (a) Any unexercised portion of the Option shall automatically and without notice terminate and
become null and void at the time of the earliest to occur of:

          (i) three (3) months after the date on which the Optionee’s service with the Company and its
Subsidiaries is terminated for any reason other than by reason of (A) Cause, which, solely for
purposes of this Agreement, shall mean the termination of the Optionee’s service by reason of the
Optionee’s willful misconduct or gross negligence, (B) a mental or physical disability (within the
meaning of Section 22(e) of the Internal Revenue Code of 1986, as amended) of the Optionee as
determined by a medical doctor satisfactory to the Committee, or (C) death;

          (ii) immediately upon the termination of the Optionee’s service with the Company and its
Subsidiaries for Cause;

          (iii) twelve (12) months after the date on which the Optionee’s service with the Company and
its Subsidiaries is terminated by reason of a mental or physical disability (within the meaning of
Section 22(e) of the Internal Revenue Code of 1986, as amended) as determined by a medical doctor
satisfactory to the Committee;

          (iv) twelve (12) months after the date of termination of the Optionee’s service with the
Company and its Subsidiaries by reason of the death of the Optionee (or if later, three months
after the date on which the Optionee shall die if such death shall occur during the one year period
specified in paragraph (iii) of this Section 6);

          (v) immediately in the event that the Optionee shall file any lawsuit or arbitration claim
against the Company or any Subsidiary, or any of their respective officers,
directors or shareholders of the Company;

2

 

          (vi) the tenth (10th) anniversary of the Date of Grant; or

          (vii) termination under Section 12 hereof.

     (b) To the extent not previously exercised, (i) the Option shall terminate immediately in the
event of (1) the liquidation or dissolution of the Company, or (2) any reorganization, merger,
consolidation or other form of corporate transaction in which the Company does not survive, unless
the successor corporation, or a parent or subsidiary of such successor corporation, assumes the
Option or substitutes an equivalent option or right pursuant to Section 10(c) of the Plan, and (ii)
the Committee or the Board in its sole discretion may by written notice (“cancellation notice”)
cancel, effective upon the consummation of any corporate transaction described in Subsection
8(b)(i) of the Plan in which the Company does survive, any Option that remains unexercised on such
date. The Committee or the Board shall give written notice of any proposed transaction referred to
in this Section 6(b) a reasonable period of time prior to the closing date for such transaction
(which notice may be given either before or after approval of such transaction), in order that the
Optionee may have a reasonable period of time prior to the closing date of such transaction within
which to exercise the Option if and to the extent that it then is exercisable (including any
portion of the Option that may become exercisable upon the closing date of such transaction). The
Optionee may condition his exercise of the Option upon the consummation of a transaction referred
to in this Section 6(b).

     7. Transferability. The Option granted hereby is not transferable otherwise than by
will or under the applicable laws of descent and distribution, and during the lifetime of the
Optionee the Option shall be exercisable only by the Optionee or the Optionee’s guardian or legal
representative. In addition, the Option shall not be assigned, negotiated, pledged or hypothecated
in any way (whether by operation of law or otherwise), and the Option shall not be subject to
execution, attachment or similar process. Upon any attempt to transfer, assign, negotiate, pledge
or hypothecate the Option, or in the event of any levy upon the Option by reason of execution,
attachment or similar process contrary to the provisions hereof, the Option shall immediately
become null and void.

     8. No Rights of Stockholders. Neither the Optionee nor any personal representative
(or beneficiary) shall be, or shall have any of the rights and privileges of, a stockholder of the
Company with respect to any shares of Stock purchasable or issuable upon the exercise of the
Option, in whole or in part, prior to the date of exercise of the Option.

     9. Stockholders Agreements; Restrictions.

     (a) Stockholders Agreement. Unless the requirements under this sentence are waived in
writing by the Company, the Optionee shall not be permitted to exercise the Option or to be issued
any shares of Stock thereunder unless and until the Optionee executes and delivers to the Company
the form of stockholders agreement then in effect among the Company and its stockholders (which
agreement may be the stockholders agreement utilized in connection with the Company’s initial
private offering to investors) (the “Stockholders Agreement”). In addition to any rights or
obligations of Optionee under such Stockholders Agreement, the Optionee is and shall be subject to
the following provisions of this Section 9 and the other provisions of this Option Agreement.

3

 

     (b) Restrictions While Stock is Not Registered; Restricted Shares. The shares of
Stock subject to the Option specified in Section 1 and (i) all shares of the Company’s capital
stock received as a dividend or other distribution upon such shares, and (ii) all shares of capital
stock or other securities of the Company into which such shares may be changed or for which such
shares shall be exchanged, whether through reorganization, recapitalization, stock split-ups or the
like, shall be subject to the provisions of this Section 9 at all times, and only at those times,
that shares of the Company’s Common Stock are not Publicly-Held (such times during which the Stock
is not so Publicly-Held hereinafter being referred to as the “Restricted Period”) and are during
the Restricted Period hereinafter referred to as “Restricted Shares.” For purposes of this
Agreement, “Publicly-Held” means that the Common Stock of the Company, or the stock of any
successor company into which the Common Stock is substituted or exchanged, is registered pursuant
to Section 12(b) or 12(g) of the Securities Exchange Act.

     (c) No Sale or Pledge of Restricted Shares. Except as otherwise provided herein, the
Optionee agrees and covenants that during the Restricted Period he or she will not sell, pledge,
encumber or otherwise transfer or dispose of, and will not permit to be sold, encumbered, attached
or otherwise disposed of or transferred in any manner, either voluntarily or by operation of law
(all hereinafter collectively referred to as “transfers”), all or any portion of the Restricted
Shares or any interest therein except in accordance with and subject to the terms of this Section
9.

     (d) Involuntary Transfer Repurchase Option. Whenever, during the Restricted Period,
the Optionee has any notice or knowledge of any attempted, pending, or consummated involuntary
transfer or lien or charge upon any of the Restricted Shares, whether by operation of law or
otherwise, the Optionee shall give immediate written notice thereof to the Company. Whenever the
Company has any other notice or knowledge of any such attempted, impending, or consummated
involuntary transfer, lien, or charge, it shall give written notice thereof to the Optionee. In
either case, the Optionee agrees to disclose forthwith to the Company all pertinent information in
his possession relating thereto. If during the Restricted Period any of the Restricted Shares are
subjected to any such involuntary transfer, lien, or charge, the Company and its designated
purchaser shall at all times have the immediate and continuing option to purchase such of the
Restricted Shares upon notice by the Company to the Optionee or other record holder at a price
determined according to Section 9(f) below, and any of the Restricted Shares so purchased by the
Company or its designated purchaser shall in every case be free and clear of such transfer, lien,
or charge.

     (e) Repurchase Option on Termination of Service. Anything set forth in this Agreement
to the contrary notwithstanding, the Company shall have the right (but not the obligation) to
purchase or designate a purchaser of all, but not less than all, of the Restricted Shares
(including, without limitation, any Restricted Shares transferred pursuant to Section 2.3.1 of the
Stockholders Agreement) during the Restricted Period and after termination of the Optionee’s
service as a Director or independent contractor with the Company for any reason, for the purchase
price specified in Section 9(f) hereof. The Company may exercise its right to purchase or
designate a purchaser of the Restricted Shares at any time (without any time limitation) after the
Optionee’s termination of employment or service and during the Restricted Period. If the Company
chooses to exercise its right to purchase the Restricted Shares hereunder, the Company shall give
its notice of its exercise of this right to the Optionee or his or her legal representative
specifying in such notice a date not later than ten (10) days following the date of giving such
notice on which the Company or its designated purchaser shall deliver, or be

4

 

prepared to deliver
the check or promissory note for the purchase price and the Optionee or his or her legal
representative shall deliver all stock certificates evidencing such Restricted Shares duly endorsed
in blank for transfer or with separate stock powers endorsed in blank for transfer.

     (f) Repurchase Price. For purposes of Section 9(d) and (e) hereof, the per share
purchase price of Restricted Shares shall be an amount equal to the Fair Market Value of such
share, determined by the Board or the Committee as of any date determined by the Board or the
Committee that is not more than one year prior to the date of the event giving rise to the
Company’s right to purchase such Restricted Shares under this Section 9. Any determination of Fair
Market Value made by the Board or the Committee shall be binding and conclusive on all parties
unless shown to have been made in an arbitrary and capricious manner. The purchase price shall, at
the option of the Company, be payable in cash or in the form of the Company’s promissory note
payable in up to three equal annual installments commencing 12 months after the acquisition by the
Company (“Acquisition Date”) of the Restricted Shares, together with interest on the unpaid balance
thereof at the rate equal to the prime rate of interest of Citibank, N.A. on the Acquisition Date.

     (g) Voting Rights. As a condition to Optionee’s exercise of any Option pursuant to
this Agreement, the Company may in its discretion require that Optionee enter into a voting
agreement that grants to specified persons designated therein the voting rights for all shares of
Stock acquired pursuant to the exercise of such Options, until the earlier of (i) 10 years from the
date of exercise of the Option, or (ii) the end of the Restricted Period, such voting agreement to
be in such form as the Company reasonably may request.

     (h) Legends. The certificate or certificates representing any Shares acquired
pursuant to the exercise of an Option prior to the last day of the Restricted Period shall bear the
following legends (as well as any legends required by applicable state and federal corporate and
securities laws or the Stockholders Agreement):

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE
ACT OR, IN THE OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE
ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR
HYPOTHECATION IS IN COMPLIANCE THEREWITH.

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN
RESTRICTIONS ON TRANSFER, RIGHT OF FIRST REFUSAL AND REDEMPTION OR
REPURCHASE OPTIONS HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE
STOCK OPTION AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE
SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE
ISSUER. SUCH TRANSFER RESTRICTIONS, RIGHT OF FIRST REFUSAL AND REDEMPTION
OR REPURCHASE RIGHTS ARE BINDING ON TRANSFEREES OF THESE SHARES.

5

 

     10. Market Stand-Off Agreement. In the event of an initial public offering of the
Company’s securities and upon request of the Company or the underwriters managing any underwritten
offering of the Company’s securities, the Optionee agrees not to sell, make any short sale of,
loan, grant any option for the purchase of, or otherwise dispose of any Shares (other than those
included in the registration) acquired pursuant to the exercise of the Option, without the prior
written consent of the Company or such underwriters, as the case may be, for such period of time
(not to exceed 180 days) from the effective date of such registration as may be requested by the
Company or such managing underwriters.

     11. Optionee’s Representations. By executing this Agreement, Optionee hereby
represents and warrants to the Company as to all provisions set forth in the Investment
Representation Statement attached hereto as Exhibit A. In addition, in the event the Company’s
issuance of the Shares purchasable pursuant to the exercise of this Option has not been registered
under the Securities Act of 1933, as amended, at the time this Option is exercised, Optionee shall,
if required by the Company, concurrently with the exercise of all or any portion of this Option,
execute and deliver to the Company such Investment Representation Statement or such other form as
the Company may request.

     12. Acceleration of Exercisability of Option. Except as otherwise determined by the
Board or the Committee, in its sole and absolute discretion, this Option shall become immediately
exercisable in the event of a Change in Control, or in the event the Committee or the Board
exercises its discretion to cancel the Option pursuant to Sections 6(b) or (c) hereof.

     13. No Right to Continued Service. Neither the Option nor this Agreement shall confer
upon the Optionee any right to continued service with the Company.

     14. Law Governing. This Agreement shall be governed in accordance with and governed
by the internal laws of the State of Florida.

     15. Interpretation. The Optionee accepts the Option subject to all the terms and
provisions of the Plan and this Agreement. The undersigned Optionee hereby accepts as binding,
conclusive and final all decisions or interpretations of the Committee upon any questions arising
under the Plan and this Agreement.

     16. Notices. Any notice under this Agreement shall be in writing and shall be deemed
to have been duly given when delivered personally or when deposited in the United States mail,
registered, postage prepaid, and addressed, in the case of the Company, to the Company’s Secretary
at 2400 N. Commerce Parkway, Suite 408, Ft. Lauderdale, Florida 33326, or if the Company should
move its principal office, to such principal office, and, in the case of the Optionee, to the
Optionee’s last permanent address as shown on the Company’s records, subject to the right of either
party to designate some other address at any time hereafter in a notice satisfying the requirements
of this Section.

     17. Tax Consequences. Set forth below is a brief summary as of the date of this
Option of certain of the federal tax consequences of exercise of this Option and disposition of the
Shares under the law in effect as of the date of grant. THIS SUMMARY IS NECESSARILY INCOMPLETE,
AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE. OPTIONEE SHOULD CONSULT A TAX ADVISER
BEFORE EXERCISING THIS OPTION OR DISPOSING OF THE SHARES.

6

 

     There may be a regular federal income tax liability upon the exercise of the Option. Optionee
will be treated as having received compensation income (taxable at ordinary income tax rates) equal
to the excess, if any, of the fair market value of the Shares on the date of exercise over the
Exercise Price. If Optionee is an employee, the Company will be required to withhold from
Optionee’s compensation or collect from Optionee and pay to the applicable taxing authorities an
amount equal to a percentage of this compensation income at the time of exercise. Any gain
realized on disposition of the Shares will be treated as short-term or long-term capital gain for
federal income tax purposes, depending upon whether the Shares have been held for at least one year
following exercise of the Option.

     IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the                  day of                 .

	 	 	 	 	 
	 	COMPANY:

BIOHEART, INC.

 	 
	 	By:  	 	 
	 	 	 	 
	 	 	 	 
	 

7

 

     Optionee acknowledges receipt of a copy of the Plan and represents that he or she is familiar
with the terms and provisions thereof, and hereby accepts this Option subject to all of the terms
and provisions thereof. Optionee has reviewed the Plan and this Option in their entirety, has had
an opportunity to obtain the advice of counsel prior to executing this Option, and fully
understands all provisions of the Option.

	 	 	 	 	 
	Dated: _______________________	OPTIONEE:

 	 
	 	By:  	 	 
	 	 	 	 
	 	 	 	 

8

 

	 	 	 	 	 

EXHIBIT A

INVESTMENT REPRESENTATION STATEMENT

	 	 	 	 	 
	PURCHASER

	 	:	 	 
	 
	 	 	 	 
	COMPANY

	 	:
	 	BIOHEART, INC.
	 
	 	 	 	 
	SECURITY

	 	:
	 	COMMON STOCK
	 
	 	 	 	 
	AMOUNT

	 	:	 	 
	 
	 	 	 	 
	DATE

	 	:	 	 

In connection with the grant and exercise of options to purchase of the above-listed Securities, 1,
the Purchaser, represent to the Company the following:

     (a) I am aware of the Company’s business affairs and financial condition, and have acquired
sufficient information about the Company to reach an informed and knowledgeable decision to acquire
the Securities. I am purchasing these Securities for my own account for investment purposes only
and not with a view to, or for the resale in connection with, any “distribution” thereof for
purposes of the Securities Act of 1933, as amended (the “Securities Act”).

     (b) I understand that the Company’s issuance of the Securities has not been registered under
the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon,
among other things, the bona fide nature of my investment intent as expressed herein. In this
connection, I understand that, in the view of the Securities and Exchange Commission (the “SEC”),
the statutory basis for such exemption may be unavailable if my representation was predicated
solely upon a present intention to hold these Securities for the minimum capital gains period
specified under tax statutes, for a deferred sale, for or until an increase or decrease in the
market price of the Securities, or for a period of one year or any other fixed period in the
future.

     (c) I further understand that the Securities must be held by me indefinitely unless the
transfer is subsequently registered under the Securities Act or unless an exemption from
registration is otherwise available, and that I cannot transfer or sell any Securities unless
permitted under my Stock Option Agreement and the Stockholders Agreement referenced in Section 9(a)
of this Stock Option Agreement. Moreover, I understand that the Company is under no obligation to
register any transfer of the Securities. In addition, I understand that the certificate evidencing
the Securities will be imprinted with a legend which prohibits the transfer of the Securities
unless registered or such registration is not required in the opinion of counsel for the Company.

     (d) I am familiar and agree to comply with the provisions of Rule 701 and Rule 144, each
promulgated under the Securities Act, which, in substance, permit limited public resale of
“restricted securities” acquired, directly or indirectly, from the issuer thereof, in a non-public
offering subject to the satisfaction of certain conditions, subject to the requirements of my Stock
Option Agreement and the Stockholders Agreement.

Signature of Purchaser:

 

______________________________________

Date: _________________

9Ex-10.20 Material Supply Agreement

 

Exhibit 10.20

Material Supply Agreement

This Material Supply Agreement (the “Agreement”) is made effective as of the last date of the signatures below written (the
“Effective Date”) between Biosense Webster with an address at 21700 Copley Drive, Suite 320, Diamond Bar, CA 91765 (“BWI”) and
Bioheart lnc with an address at 13794 NW4th Street, Suite 212, Sunrise, Florida 33325 (“Company”).

Now, therefore, in consideration of the mutual promises and understandings and other good and valuable consideration, the receipt of
which is hereby acknowledged, the parties agree as follows:

1. BWI will supply MyoStarTM Injection Catheters (“Devices”) at a research price of $1,450
per unit to the Company. The Company desires to use such Devices for research purposes as
described in the attached clinical protocol (“Study”) (attached hereto as Appendix A). The study
shall be conducted under the supervision of the named Principal Investigator as determined by
the Company. In addition, BWI will facilitate purchasing access to our FDA approved mapping
and reference catheters (Nogastar and Refstar respectively) by setting up Company as an
approved purchaser with Johnson and Johnson Healthcare Systems. The Company agrees that
the Myostar catheter can only be used with the approved Noga XP cardiac mapping system.

2. Company shall assume all regulatory responsibilities of sponsor-investigators. In addition
to any reports required by applicable regulations, Company shall provide to BWI the following:
(1) within twenty-four (24) hours of receipt, reports of any death or serious injury sustained by a
subject or any malfunction of the Study Devices occurring during the collection of data; (2) a copy
of any communication or report to the FDA related to the Study Device, to be sent to BWI
simultaneously with submission to FDA; and (3) within seven (7) days of receipt, any other
complaints, defined as any written, electronic, or oral communication that alleges deficiencies
related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a BWI
device after it is released for distribution (this includes marketed product that is utilized in a
clinical study/registry), about the Study Device. Copies of such reports shall be provided to BWI
within twenty-four (24) hours of observing or being informed of the event, and shall be forwarded
via fax:

Biosense Webster Complaint Handling Unit:

Phone: 1-866-473-7823

Fax: 909-839-7335

Address: Biosense Webster, Inc.

Product Returns (Complaint Number: XYZ)

Lab 103

15715 Arrow Hwy.

Irwindale, CA 91706

In addition, Company agrees to follow-up on safety information related to the study device as requested by BWI.

3. At BWI’s request, Company will provide a written assessment of the performance of the
Device within 45 days following completion of the Study.

4. Delivery of such Devices shall be made by BWI to the Company as and when required
for performance of the Study. BWI warrants that the Devices shall be in conformance with all
applicable federal, state or municipal statutes, laws, rules or regulations, including those enforced
or promulgated by the United States Food and Drug Administration. BWI will invoice the
Company on a monthly basis for all Devices shipped.

5. Within thirty (30) days prior to the expiration date of a Device, the Company may return
the Device to BWI for a replacement Device.

1 of 5

 

6. At no charge, BWI shall provide reasonable training and support in the use of all required
BWI products to the Principal Investigators for the Study, at any and ail clinical sites, as and when
required for performance of the Study.

7. Company acknowledges that they are the sponsor of the Study, and that BWI will not be
responsible for the use of the products in connection with the Study. Company and Principal
Investigators shall be responsible for complete device accountability in accordance with the
United States Food and Drug Administration (“FDA”) regulations.

8. Company shall not disclose any BWI Information to any third party, nor use the same for
its own benefit, nor permit its use for the benefit of others without the prior written consent of BWI. Company may disclose BWI information to its employees and contractors who are involved in
performing the Study and who have undertaken, in writing, obligations of confidentiality with
respect to such BWI information at least as restrictive as set forth in this Agreement.

8.5 BWI recognizes that the results of the clinical research must be publishable. Subject to the provisions of this Agreement, the
Company, Principal Investigator, or other Investigators engaged in the clinical research shall be permitted to present at symposia,
national or regional professional meetings, and to publish in journals, theses, dissertations or otherwise, the methods and results
of the clinical research, in the form of presentations, journal articles, papers or otherwise. Company shall furnish BWI with two
copies of any proposed publications or presentations at least sixty (60) days before their submission for publication or presentation.

9. The term of this agreement shall be two (2) years beginning on the Effective Date, or until
three months after the final procedure is performed on the final patient enrolled in the Study,
whichever comes first, unless the Agreement is terminated earlier. The parties may extend the
term of this Agreement by written agreement. In addition, Company acknowledges that the
Clinical Study Protocol is still being drafted, and as such, this agreement can be terminated if the
Study Protocol is not deemed acceptable by BWI.

10. Compliance. The parties represent that they understand and agree that the Study under
this Agreement shall be provided in compliance with all laws and regulations applicable to such
Study, including, but not limited to, the following:

	 	(a)	 	Health Care Compliance Laws. Laws, regulations, including safe harbor
regulations, and official guidance pertaining to state and federal anti-kickback
laws (42 U.S.C. §§ 1320a-7b(b), et seq. and its implementing regulations), and
laws prohibiting the submission of false claims to governmental or private health
care payors (31 U.S.C. §§ 3729, et seq. and its implementing regulations).
	 
	 	(b)	 	Patient and Individual Privacy Protections. Laws and regulations relating to the
protection of individual and patient privacy.

	 	(i)	 	Protected Health information under HIPAA. In the event that any Study provided under this Agreement involves the
use or disclosure of Protected Health Information (as defined under the U.S. HIPAA Privacy Requirements) by
health care providers, the Parties shall ensure that the use of the Protected Health Information complies with
any HIPAA Privacy Requirements that apply to such Protected Health Information. The “HIPAA Privacy
Requirements” refer collectively to the applicable provisions of the Administrative Simplification section of
HIPAA — the Health Insurance Portability and Accountability Act of 1996 (as codified at 42 U.S.C. § 1320d -d-8)
and any regulations promulgated thereunder, including without limitation, the federal privacy regulations (45
CFR Parts 160 and 164) and the federal security standards (45 CFR Part 142).

2 of 5

 

	 	(ii)	 	Consent to Use and Disclose Information. When the Study involves direct interactions with patients, consumers
or caregivers, the parties shall obtain written consent from any such persons providing BWI the right to use
and disclose the information collected from such persons.

	 	(c)	 	Exclusion and Debarment Lists; State Licensing. Ensure that Company is:

	 	(i)	 	not excluded from a federal health care program as outlined in Sections 1128 and 1156 of the Social Security
Act (see the Office of Inspector General of the Department of Health and Human Study
List of Excluded Individuals/Entities at 
http://www.oig.hhs.gov/FRAUD/exclusions/listofexcluded.html).
	 
	 	(ii)	 	not debarred by the FDA under 21 U.S.C. 335a (see the FDA Office of Regulatory Affairs Debarment List at
http://www.fda.gov/ora/compliance_ref/debar/).
	 
	 	(iii)	 	otherwise not excluded from contracting with the federal government (see the Excluded Parties Listing System
at http://epls.arnet gov).
	 
	 	(iv)	 	if required, duly licensed and in good standing in accordance with applicable state laws to provide the Study.

11. The Company warrants that it has adequate liability insurance, such protection being
applicable to Company’s employees and agents while acting within the scope of their
employment by Institution.

12. BWI shall not be liable for any indemnification or expenses for actions or claims in any
way arising from or caused by the willful, reckless, or negligent acts or omissions, or professional
malpractice of any institution or other associates involved in the Study, or arising from their failure
to comply with the protocol, BWI’s written recommendations and instructions relative to the use of
the device(s) involved in the research, or with any applicable FDA or other foreign regulatory
bodies’ requirements or law .

13. Either party may terminate this Agreement upon thirty (90) days written notice if the
Principal Investigator becomes unable or unwilling to continue performance of the Study.

14. In the event of termination for whatever reason, the parties agree to cooperate and take
all reasonable steps necessary to discontinue ongoing activities under this Agreement to protect
the safety and well-being of patients enrolled in the Study.

15. All communications hereunder shall be deemed made if given by facsimile, by registered
or certified mail, postage prepaid and addressed to the party to receive such communication at
the address given below, or such other address as may hereafter be designated by notice in
writing:

3 of 5

 

	 	 	 
	If to BWI:

	 	Biologics Delivery Systems
	 

	 	21700 E Copley Dr., Suite 320
	 

	 	Diamond Bar, CA 91765
	 

	 	Attention: Jerett Creed
	 

	 	Facsimile: 909-839-7335
	 
	 	 
	If to Company:

	 	Bioheart Inc.
	 

	 	13794 NW 4th Street, Suite 212
	 

	 	Sunrise, Florida 33325
	 

	 	Attention: Bill Pinon
	 

	 	Facsimile: 954- 845-9976

16. Dispute Resolution. Any controversy or claim arising out of or relating to this Agreement shall be resolved by binding
arbitration before a single arbitrator in accordance with the Commercial Arbitration Rules of the American Arbitration Association
(“AAA”) then pertaining (available at www.adr.org), except where those rules conflict with this provision, in which case this
provision controls. Any court with jurisdiction shall enforce this clause and enter judgment on any award. The arbitrator shall be
selected within twenty business days from commencement of the arbitration from the AAA’s National Roster of Arbitrators pursuant to
agreement or through selection procedures administered by the AAA. Within 45 days of initiation of arbitration, the parties shall
reach agreement upon and thereafter follow procedures, including limits on discovery, assuring that the arbitration will be concluded
and the award rendered within no more than eight months from selection of the arbitrator or, failing agreement, procedures meeting
such time limits will be designed by the AAA and adhered to by the parties. The interpretation and enforcement of this arbitration
provision shall be governed by the Federal Arbitration Act. Prior to commencement of arbitration, emergency relief is available from
any court to avoid irreparable harm. THE ARBITRATOR SHALL NOT AWARD EITHER PARTY PUNITIVE, EXEMPLARY, MULTIPLIED OR CONSEQUENTIAL
DAMAGES, OR ATTORNEYS FEES OR COSTS.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed in duplicate as of the date of the last signature below
written.

	 	 	 	 	 
	 	Biosense Webster Inc

 	 
	 	By:  	/s/ Rob Pike	 
	 	 	Title:  Vice President 	 
	 	 	Date:   05/10/07 	 
	 

	 	 	 	 	 
	 	Bioheart Inc

 	 
	 	By:  	/s/ William M. Pinon 	 
	 	 	Title:   CEO and President 	 
	 	 	Date:   05/04/07 	 

4 of 5

 

	 	 	 	 	 

Appendix A

5 of 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]